AlphAIAlphAI — Financial news for AI agents
investing.comSEP 111 min read$NBIX

Neurocrine Biosciences CCO Eric Benevich sells $333k in stock

Neurocrine Biosciences (NBIX) CCO Eric Benevich sold $333k in stock on Sept 9, 2026, part of a 10b5-1 plan. He also acquired 3,194 shares via option exercise. NBIX trades at $156.57, with a $15.77B market cap. Q2 earnings beat estimates, with Ingrezza sales at $716M. Analysts raised price targets, citing strong growth prospects.

Original reporting
investing.com
Published Sep 11, 2026, 1:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 7:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$NBIX
Neutral
medium confidence
Mentioned
$NBIX
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NBIXNeutralLow
01

Why it matters

The insider transaction adds a modest data point but does not materially change the bullish outlook from recent earnings.

02

Market read

Primary relevance is to NBIX shareholders; broader market impact is minimal.

03

What to watch

Potential upcoming clinical data could outweigh insider sale signal.

Relevance 5/10Novelty 6/10Timing: recent filing Sep 9 2026

Background

NBIX reported strong Q2 earnings and raised price targets earlier; this filing follows that news.

Company-level read

Ticker impact

$NBIXNeutralMedium confidence
Context

Form 4 filing shows CCO sold $333k of NBIX shares and bought options, indicating insider activity.

Expected impact

Minor downward pressure, but likely muted due to small size relative to market cap.

Evidence & confidence

Sale represents less than 0.02% of float; insider also bought options, suggesting mixed signal.

Market effects

Sector

Limited effect on biotech sector; similar insider sales are common.

Regional

No regional impact beyond NBIX.

Global

Negligible global relevance.

Counterpoint

What could challenge this read

Insider purchase of options may signal confidence despite share sale.

Key entities

  • Company
    Neurocrine Biosciences

    Biotech firm with recent earnings beat.

  • Executive
    Eric Benevich

    Chief Commercial Officer executing a Rule 10b5-1 plan.

Read at source← All news

Related articles

SEP 18
$NBIXMedAI 8/10

Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story

Neurocrine Biosciences (NBIX) reported positive Phase 4 study results for INGREZZA, showing significant patient improvement in tardive dyskinesia. The company also reported Q2 revenue growth of 39% to $959M, with INGREZZA sales up 15%. Neurocrine acquired Soleno Therapeutics, reducing cash reserves but expanding its drug portfolio. The stock trades at a forward P/E of 14.88.

insidermonkey.com2 min
AUG 12
$NBIXMed

Why is Neurocrine Biosciences stock sliding today?

Neurocrine Biosciences (NBIX) shares fell about 3.1% to $156.94 after three Prader-Willi patient groups issued a joint statement citing post-marketing safety data for Neurocrine’s Vykat XR, including seven patient deaths and 100+ serious adverse events reported to the FDA. The groups did not claim causality. CEO Kyle Gano disputed a link. Investors also weighed INGREZZA drug-pricing concerns; Q2 2026 revenue was reported above $950M.

investing.com6 min